General Dynamics Corp.’s (GD) business unit, Bath Iron Works, recently clinched a modification contract to provide planning yard support for the DDG 51 warships. The award has been offered by the Supervisor of Shipbuilding, Conversion, and Repair, Bath, ME.Valued at $216.5 million, this contract is expected to be completed by July 31, 2026. The work related to this deal will be carried out in Bath, ME.What’s Favoring GD Stock?Heightened geopolitical tensions worldwide and the resultant need for enhanced mar ...

Investcorp Credit Management BDC (ICMB) Q3 2025 Earnings Call May 14, 2025 10:00 AM ET Company Participants Walter Tsin - Principal & CFOSuhail Shaikh - President & CEOAndrew Muns - COOPaul Johnson - Vice PresidentChristopher Nolan - SVP - Equity Research Operator Good morning, ladies and gentlemen, and welcome to today's Investcorp Credit Management BDC's quarter ended 03/31/2025 earnings call. It is now my pleasure to turn the floor over to Walter Tin, CFO. Walter Tsin Thank you, operator. Welcome everyon ...

Stellus Capital Investment (SCM) Q1 2025 Earnings Call May 13, 2025 12:00 PM ET Company Participants Robert Ladd - Managing Partner & CEOTodd Huskinson - Partner, CFO, Chief Compliance Officer, Treasurer and SecretaryErik Zwick - Managing Director, Equity ResearchChristopher Nolan - Senior VP - Equity Research Conference Call Participants Robert Dodd - Director - Equity Analyst Operator Good morning, ladies and gentlemen, and thank you for standing by. At this time, I would like to welcome everyone to Stell ...

Core Insights - EfTEN Real Estate Fund AS reported strong financial results in April, with consolidated rental income reaching 2,611 thousand euros, a month-over-month increase of 55 thousand euros driven by new rental payments from the ICONFIT logistics centre and the Hiiu elderly care home [1] - The Fund's EBITDA for April was 2,183 thousand euros, reflecting a month-over-month increase of 193 thousand euros due to higher rental income and lower expenses [2] - The Fund paid a record dividend of 12.7 million euros in April, or 1.11 euros per share, partially financed by refinancing bank loans totaling 6.3 million euros [3] - The weighted average interest rate decreased to 4.21% in April from 4.37% in March, with a year-over-year decrease in consolidated interest expense of 586 thousand euros [4] - For the first four months of 2025, consolidated rental income was 10.3 million euros, a 1% year-over-year increase, while consolidated EBITDA was 8.4 million euros, down from 8.6 million euros in the same period last year [5] - The Fund's net asset value (NAV) per share was 19.64 euros at the end of April, with an EPRA NRV of 20.50 euros; the NAV decreased by 5.3% due to the dividend distribution [6]

INVESTOR PRESENTATION 1st Quarter 2025 Legal Disclaimer FORWARD-LOOKING STATEMENTS THIS PRESENTATION INCLUDES FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. ALL STATEMENTS, OTHER THAN STATEMENTS OF PRESENT OR HISTORICAL FACT, THAT ADDRESS THE FUTURE FINANCIAL PERFORMANCE OF MOBILE INFRASTRUCTURE CORPORATION (THE "COMPANY"), AS WELL AS THE COMPANY'S STRATEGY, FUTURE OPERATIONS, FUTURE OPERATING RESULTS, FINANCIAL POSITION, ESTIMATED REVENUES, AND LOSSES ...

NextNav (NN) Q1 2025 Earnings Call May 09, 2025 09:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the NexNav First Quarter twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer I would now like to turn the conference over to Nevin Riley. You may begin. Speaker1 G ...

FCC releases Notice of Inquiry (NOI) with bipartisan 4-0 vote NextNav Announces Appointment of Rear Admirals H. Wyman Howard and Lorin Selby to its Board of Directors RESTON, Va., May 09, 2025 (GLOBE NEWSWIRE) -- NextNav Inc. (NASDAQ: NN) a leader in next generation positioning, navigation, and timing (PNT) and 3D geolocation, today reported its financial results and operational updates for the quarter ended March 31, 2025. “During the quarter we saw continued FCC momentum with a unanimous vote in March to ...

Farmland Partners (FPI) Q1 2025 Earnings Call May 08, 2025 11:00 AM ET Company Participants Luca Fabbri - President and CEOChristine Garrison - General Counsel & Corporate SecretaryPaul Pittman - Executive ChairmanSusan Landi - CFOCraig Kucera - MD - Equity Research Conference Call Participants John Massocca - Senior Research Analyst Operator Thank you for standing by. My name is Amy, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Farmland Partners Fi ...

Farmland Partners (FPI) Q1 2025 Earnings Call May 08, 2025 11:00 AM ET Speaker0 Thank you for standing by. My name is Amy, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Farmland Partners First Quarter twenty twenty five Earnings a It is now my pleasure to turn the call over to Luca Fabri, the President and CEO with Farmland Partners. You may begin. Speaker1 Thank you, Amy. Good morning, and welcome everybody to Farmland Partners first quarter twenty ...

Core Viewpoint - Dogwood Therapeutics, Inc. is advancing its Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study, with interim data expected in Q4 2025, while maintaining a strong financial position with $17.5 million in cash to support operations through Q1 2026 [1][6]. Company Developments - The company has commenced dosing patients in the Halneuron® Phase 2b study, which aims to be the first FDA-approved therapy for chemotherapy-induced neuropathic pain [6]. - Halneuron® has received fast track designation from the FDA for the treatment of chemotherapy-induced neuropathic pain [6]. - An affiliate of the largest shareholder converted a $19.5 million loan into equity, enhancing the company's balance sheet [6]. - A recent capital raise of $4.8 million, combined with existing cash, provides operational runway through Q1 2026 [6]. Financial Performance - Research and development expenses for Q1 2025 were $2.4 million, a significant increase from $0.3 million in Q1 2024, primarily due to the business combination with Pharmagesic and increased clinical trial expenses [5]. - General and administrative expenses rose to $2.0 million in Q1 2025 from $1.0 million in Q1 2024, driven by higher legal and accounting fees [7]. - The net loss attributable to common stockholders for Q1 2025 was $12.2 million, compared to a net loss of $1.3 million in Q1 2024, reflecting a substantial increase in operational costs [8][14]. Research Pipeline - The proprietary pipeline includes Halneuron® as a non-opioid NaV 1.7 inhibitor for pain conditions, with interim data from the ongoing Phase 2b study expected in Q4 2025 [9]. - IMC-1 and IMC-2 are antiviral treatments in development, with IMC-1 ready for Phase 3 for fibromyalgia and IMC-2 in Phase 2a for Long-COVID [10].